CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers
Year: 2026
Type: preprint
Study design: Clinical Trial
Abstract: Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naïve and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally. STATEMENT OF SIGNIFICANCE The first-in-human study of the safety and efficacy of a defined bacterial consortium in combination with anti-PD-1 treatment in various solid tumors demonstrated the safety of the combination, albeit with low clinical efficacy. The results provide important knowledge and considerations about microbiome modulation in cancer, to help design future trials.
Source: medRxiv
Institutions: GlaxoSmithKline (United States), Vedantra Pharmaceuticals (United States), University of Massachusetts Chan Medical School, CSL (Switzerland), Veeva Systems (United States), Ferring Pharmaceuticals (United States), Icahn School of Medicine at Mount Sinai, Keio University, RIKEN Center for Integrative Medical Sciences, Keio University Human Biology-Microbiome-Quantum Research Center, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Bristol-Myers Squibb
OpenAlex ID: W7235185153
